Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The first trial of robot-assisted eye surgery in patients has shown the technique to be both safe and effective.

Researchers from the Nuffield Department of Clinical Neurosciences at the University of Oxford have completed the first successful trial of robot-assisted retinal surgery.

The trial, supported by the National Institute for Health Research Oxford Biomedical Research Centre, took place at Oxford’s John Radcliffe Hospital. It involved 12 patients and is published this week in Nature Biomedical Engineering. Half were randomly allocated robot-assisted surgery and the other half to standard manual surgery to remove a membrane from the back of the eye. Using the robot, the surgeon was able to perform the procedure with equal or better efficacy than in the traditional manual approach. In the second phase of the trial, the team used the robot to insert a fine needle under the retina to dissolve blood in three patients who had age-related macular degeneration - all experienced an improvement in their vision as a result.

Robert MacLaren, Professor of Ophthalmology at the University of Oxford commented: ‘This is a huge leap forward for delicate and technically difficult surgery, which in time should significantly improve the quality and safety of this kind of operation. The trial also showed that the robot has great potential for extending the boundaries of what we can currently achieve.

‘Our next step will be to use the robotic surgical device for precise and minimally traumatic delivery of a gene therapy to the retina, which will be another first-in-man achievement and is set to commence in early 2019.’

Professor Marc D. de Smet, MD, Chief Medical Officer of Preceyes bv, the Dutch medical robotics firm that designed and developed the PRECEYES Surgical System commented: “The current trial demonstrated and confirmed the safety and precision of our design. Providing precision,accuracy and stability beyond human capabilities are pre-requisites to push the boundaries of existing surgeries and standardizing current procedures.”

The surgery involved the dissection of the epiretinal membrane and inner limiting membrane over the macula, the central region of the retina responsible for fine visual acuity, in six of the patients, as well as the injection of a therapeutic drug (recombinant tissue plasminogen activator) under the retina to displace sight-threatening haemorrhage in three patients.

In 2016 Oxford University signed an agreement with Preceyes to test the robotic surgical system, and a team led by eye surgeon and researcher Professor Robert MacLaren began the human clinical trials using the PRECEYES Surgical System.

Similar stories

Bioelectronic implant offers an intelligent therapy to treat incontinence

The first participants in a clinical trial of a bioelectrical therapy to treat incontinence have received their 'smart' bioelectronic implants.

Direct evidence of reduced NMDA receptors in people with form of encephalitis

NMDAR-antibody encephalitis is an autoimmune brain condition caused by patient’s own antibodies that bind to NMDA (N-Methyl-D-Aspartate) receptors in the synapses between nerve cells.

Director of MRC Brain Network Dynamics Unit appointed

From 2 January 2023, Professor Peter Magill will lead the Medical Research Council Brain Network Dynamics Unit (MRC BNDU) at the University of Oxford.

Study reveals association between diagnosis of a neuropsychiatric condition and severe outcome from COVID-19 infection, and other severe acute respiratory infections

New research from the University of Oxford has shown an increased risk of severe illness and death from both COVID-19 and other severe respiratory infections, such as influenza and pneumonia, among people with a pre-existing mental health condition.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.